These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10500778)

  • 1. Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS.
    Wattel E; Solary E; Hecquet B; Caillot D; Ifrah N; Brion A; Milpied N; Janvier M; Guerci A; Rochant H; Cordonnier C; Dreyfus F; Veil A; Hoang-Ngoc L; Stoppa AM; Gratecos N; Sadoun A; Tilly H; Brice P; Lioure B; Desablens B; Pignon B; Abgrall JP; Leporrier M; Fenaux P
    Adv Exp Med Biol; 1999; 457():35-46. PubMed ID: 10500778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study.
    Wattel E; Solary E; Hecquet B; Caillot D; Ifrah N; Brion A; Mahé B; Milpied N; Janvier M; Guerci A; Rochant H; Cordonnier C; Dreyfus F; Buzyn A; Hoang-Ngoc L; Stoppa AM; Gratecos N; Sadoun A; Stamatoulas A; Tilly H; Brice P; Maloisel F; Lioure B; Desablens B; Fenaux P
    Br J Haematol; 1998 Sep; 102(4):1015-24. PubMed ID: 9734653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes.
    Wattel E; Solary E; Leleu X; Dreyfus F; Brion A; Jouet JP; Hoang-Ngoc L; Maloisel F; Guerci A; Rochant H; Gratecos N; Casassus P; Janvier M; Brice P; Lepelley P; Fenaux P
    Leukemia; 1999 Apr; 13(4):524-9. PubMed ID: 10214857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes.
    Lepelley P; Poulain S; Grardel N; Preudhomme C; Cosson A; Fenaux P
    Leuk Lymphoma; 1998 May; 29(5-6):547-51. PubMed ID: 9643568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study.
    Solary E; Witz B; Caillot D; Moreau P; Desablens B; Cahn JY; Sadoun A; Pignon B; Berthou C; Maloisel F; Guyotat D; Casassus P; Ifrah N; Lamy Y; Audhuy B; Colombat P; Harousseau JL
    Blood; 1996 Aug; 88(4):1198-205. PubMed ID: 8695837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.
    Prébet T; Ducastelle S; Debotton S; Stamatoullas A; Deconinck E; Fruchart C; Gratecos N; Ifrah N; Dreyfus F; Fenaux P; Wattel E;
    Hematol J; 2004; 5(3):209-15. PubMed ID: 15167906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).
    Greenberg PL; Lee SJ; Advani R; Tallman MS; Sikic BI; Letendre L; Dugan K; Lum B; Chin DL; Dewald G; Paietta E; Bennett JM; Rowe JM
    J Clin Oncol; 2004 Mar; 22(6):1078-86. PubMed ID: 15020609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia.
    Solary E; Drenou B; Campos L; de Crémoux P; Mugneret F; Moreau P; Lioure B; Falkenrodt A; Witz B; Bernard M; Hunault-Berger M; Delain M; Fernandes J; Mounier C; Guilhot F; Garnache F; Berthou C; Kara-Slimane F; Harousseau JL;
    Blood; 2003 Aug; 102(4):1202-10. PubMed ID: 12663440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.
    Solary E; Caillot D; Chauffert B; Casasnovas RO; Dumas M; Maynadie M; Guy H
    J Clin Oncol; 1992 Nov; 10(11):1730-6. PubMed ID: 1357108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
    Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
    Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eprenetapopt Plus Azacitidine in
    Cluzeau T; Sebert M; Rahmé R; Cuzzubbo S; Lehmann-Che J; Madelaine I; Peterlin P; Bève B; Attalah H; Chermat F; Miekoutima E; Rauzy OB; Recher C; Stamatoullas A; Willems L; Raffoux E; Berthon C; Quesnel B; Loschi M; Carpentier AF; Sallman DA; Komrokji R; Walter-Petrich A; Chevret S; Ades L; Fenaux P
    J Clin Oncol; 2021 May; 39(14):1575-1583. PubMed ID: 33600210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes.
    Lepelley P; Soenen V; Preudhomme C; Lai JL; Cosson A; Fenaux P
    Leukemia; 1994 Jun; 8(6):998-1004. PubMed ID: 7516032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
    Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC).
    Advani R; Visani G; Milligan D; Saba H; Tallman M; Rowe JM; Wiernik PH; Ramek J; Dugan K; Lum B; Villena J; Davis E; Paietta E; Litchman M; Covelli A; Sikic B; Greenberg P
    Adv Exp Med Biol; 1999; 457():47-56. PubMed ID: 10500779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
    Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
    de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
    Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
    Mawad R; Becker PS; Hendrie P; Scott B; Wood BL; Dean C; Sandhu V; Deeg HJ; Walter R; Wang L; Myint H; Singer JW; Estey E; Pagel JM
    Br J Haematol; 2016 Jan; 172(2):238-45. PubMed ID: 26568032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
    Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
    Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
    Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
    Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.